Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation TCT 2021

A Novel Sirolimus-Eluting Iron-Based Bioresorbable Scaffold Implantation in Single De Novo Coronary Lesions: Two-Year Clinical and Imaging Outcomes from the First in Man Study (IBS-FIM)

Presenter: Runlin Gao

November 05, 2021

Presentation TCT 2021

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

Presenter: Matthias Lutz

November 04, 2021

News Conference News TCT 2021

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

L.A. McKeown

October 25, 2021

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

News Daily News

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

L.A. McKeown

October 05, 2021

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

Shelley Wood

September 02, 2021

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Shelley Wood

August 28, 2021

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

Caitlin E. Cox

May 24, 2021

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Daily News

EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case

Yael L. Maxwell

March 03, 2021

Advertisement

A Novel Sirolimus-Eluting Iron-Based Bioresorbable Scaffold Implantation in Single De Novo Coronary Lesions: Two-Year Clinical and Imaging Outcomes from the First in Man Study (IBS-FIM)

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

Good Long-term Results With FANTOM BVS, but More Data Needed

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content